Xcout Intel
En Carta Diagnostics
En Carta Diagnostics develops diagnostic products, including an FDA Breakthrough-designated Lyme disease test, to provide rapid and accurate medical testing for patients and healthcare providers.
Subscribe to see En Carta Diagnostics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
En Carta Diagnostics at a glance
En Carta Diagnostics is a diagnostic equipment company headquartered in France. It has raised at least $7M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $5.5M in July 2026. Xcout tracks 5 named people at En Carta Diagnostics, including Guillaume Horreard (President).
En Carta Diagnostics leadership
- Guillaume HorreardPresident
- Margot KarlikowCTO & Co-founder
- Marc JulienCBDSO
- Alexander GreenStrategic Advisor & Co-founder
- Keith PardeeStrategic Advisor & Co-founder
En Carta Diagnostics funding rounds
At least $7M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $5.5M | 5 named | |
| Pre-Seed | $1.5M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
En Carta Diagnostics competitors
A few of En Carta Diagnostics's closest competitors — see the full list of competitors and alternatives →
Pictura Bio is a medical technology company developing a one-minute pathogen detection platform utilizing proprietary hardware and computer vision for infectious disease diagnostics. Its point-of-care system, which includes the PIC-ID and VISTA reader technologies, provides rapid identification and differentiation of pathogens to assist frontline healthcare providers.
Prolight Diagnostics develops innovative point-of-care in-vitro diagnostic systems that utilize proprietary digital technology to perform blood tests and deliver reliable results within minutes. The company serves healthcare providers by enabling rapid biomarker detection and decentralized testing outside of traditional hospital laboratories.
Abbott Point of Care provides rapid diagnostic testing solutions and point-of-care medical devices for healthcare professionals.
SD Biosensor is a global diagnostic reagents company that develops and supplies a wide range of diagnostic testing platforms and products, including rapid tests, molecular diagnostics, fluorescence immunoassays, and blood glucose meters. The company serves healthcare providers, laboratories, and patients by offering screening and confirmatory testing solutions for infectious diseases, chronic conditions, and other health markers.
Biofire Group develops syndromic infectious disease diagnostics systems and multiplex PCR testing panels. The company serves clinical laboratories and healthcare providers by delivering rapid detection results for pathogens such as viruses, bacteria, and resistance genes.
MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific region, and other international markets. MedMira offers a diverse portfolio of rapid diagnostic tests and technology platforms. Its diagnostic solutions include Reveal HIV, which identifies HIV-1 and HIV-2 antibodies in various blood samples; Reveal TP, a rapid test for syphilis antibodies (Treponema pallidum); and Reveal HP, designed to detect Helicobacter pylori antibodies. The company also provides Multiplo, a line of multiplex tests for combined screening of conditions such as HIV-1/2, Hepatitis B and C, and syphilis, as well as the Miriad triple product for initial HIV and hepatitis screening. In the realm of respiratory and viral diagnostics, MedMira developed VYRA CoV2 for SARS-CoV-2 nucleocapsid antigen detection, VYRA CoV2Flu for simultaneous antigen testing of SARS-CoV-2, Influenza A, and Influenza B, and REVEALCOVID-19, an antibody test for COVID-19. Beyond diagnostic kits, MedMira provides the Miriad RVF toolkit, a platform that facilitates the development and market entry of rapid diagnostics. MedMira distributes its offerings through a wide network of medical distributors and strategic partners. Its customer base is broad, serving various segments of the healthcare industry, including clinical laboratories, hospitals, point-of-care clinics, government agencies, humanitarian aid groups, and public health bodies. The company was established in 1993, is headquartered in Halifax, Canada, and operates as a subsidiary of MedMira Holding AG.
Get En Carta Diagnostics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on En Carta Diagnostics in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access